COMP <GO>
BDX vs ABBV // REVENUE GROWTH (YOY)
Becton Dickinson and Company (NYSE) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: BDX 5
— ABBV 10
▲ REVENUE GROWTH (YOY) LEADER: ABBV
LAST: $197.88 (-0.23%) • MKT CAP: $54.03B
revenue-growth
8.20%
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
revenue-growth
8.60%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BDX VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | BDX | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 45.40% | 70.20% | -24.80 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 4.90% | 29.00% | -24.10 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | 21.8x | 33.3x | -11.50 | BDX | /valuation <GO> |
| Free Cash Flow Yield | 2.13% | 3.47% | -1.34 | ABBV | /fcf-yield <GO> |
| Operating Margin | 11.80% | 24.60% | -12.80 | ABBV | /operating-margins <GO> |
| Net Profit Margin | 7.70% | 6.90% | +0.80 | BDX | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | 8.20% | 8.60% | -0.40 | ABBV | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 2.21% | 2.27% | -0.06 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.22 | 5.33 | -3.11 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | BDX | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.10% | 7.40% | -0.30 | BDX | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 64.0 | 72.8 | -8.77 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.06 | 1.15 | -0.09 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 29.9x | 113.1x | -83.20 | BDX | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $54.03B | $513.86B | -$459.83B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | BDX REV | ABBV REV | BDX GROSS % | ABBV GROSS % | BDX FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $21.84B | $61.16B | 45.4% | 70.2% | $1.12B | $17.82B |
| FY 2024 | $20.18B | $56.33B | 45.2% | 70.0% | $1.18B | $17.83B |
| FY 2023 | $19.37B | $54.32B | 44.0% | 44.0% | $790.3M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BDX // BETA 1.06
ABBV // BETA 1.15